AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

News provided by

Jun 27, 2019, 12:16 ET

NORTH CHICAGO, Ill., June 27, 2019 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Roxanne S. Austin
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	26 June 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	52,114 Common Shares (0.004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	52,114 Common Shares (0.004%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Purchase

11500 common shares

$67.50

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


Is a Supplemental Form 8 attached? (Note 9) YES/NO√


Date of disclosure	27 June 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	William J. Chase
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	26 June 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	169,552 Common Shares (0.01%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	641,027 Options (0.04%) 112,376 Performance Shares (0.01%) under AbbVie Share Plans
Total	922,955 (0.06%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Purchase

30400 common shares

$67.30

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


Is a Supplemental Form 8 attached? (Note 9) YES/NO√

Date of disclosure	26 June 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of subsidiaries of AbbVie Inc.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Edward J. Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	26 June 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	30,662 Common Shares (0.002%)
(2) Derivatives (other than options)	14,907 stock equivalent units (0.001%)
(3) Options and agreements to purchase/sell	N/A
Total	45,569 (0.003%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Purchase

7500 common shares

$67.30

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.


Is a Supplemental Form 8 attached? (Note 9) YES/NO√

Date of disclosure	27 June 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.